OTC Markets OTCPK - Delayed Quote USD

GALDERMA GROUP AG (GDERF)

108.10

0.00

(0.00%)

At close: April 11 at 4:00:00 PM EDT

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

ZUG, Switzerland, March 20, 2025--Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions. This extensive program highlights the breadth of Galderma’s leading Injectable Aesthetics portfolio, designed to addres

Business Wire 23 days ago

GALDY
0.00%
GDERF
0.00%
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience

Galderma's leading acne care line, Differin, is expanding its presence on gaming platforms as the first in its category to launch on Roblox. The brand's 'Level Up' campaign aimed at gamers, focuses on educating and empowering the gaming community to take charge of their skin health. By integrating with some of the most popular games on the platform, the 'Level Up Lobby' experience invites players into an interactive world where mini games meet skin health education, empowering the gaming communi

PR Newswire 25 days ago

GALDY
0.00%
GDERF
0.00%
Galderma Group AG (XSWX:GALD) Full Year 2024 Earnings Call Highlights: Record Sales and ...

Galderma Group AG (XSWX:GALD) reports a milestone year with record net sales and profitability, while navigating competitive pressures and market dynamics.

GuruFocus.com last month

GALDY
0.00%
GDERF
0.00%
Galderma Shares Slide on Expected Hit From Investments

The stock dropped after the skincare company warned that it expects investments in a dermatological drug to hit profitability and guided for weak sales in the first quarter.

The Wall Street Journal last month

GALDY
0.00%
GDERF
0.00%
Galderma to discuss U.S. tariffs with retailers, sees "moving target"

Swiss skincare company Galderma will talk to major American retailers about trade tariffs imposed by the U.S. government in order to manage their impact, CEO Flemming Ornskov said on Thursday. U.S. President Donald Trump this week slapped tariffs of 25% on Canada and Mexico, though his administration later said it would temporarily exempt automakers and consider other products. "We will be talking to Walmart, Target, Amazon, and others to figure out how we're going to react to this, also price-wise," Ornskov told Reuters after Galderma posted a 9.3% sales increase for 2024 and net income of $231 million.

Reuters last month

GALDY
0.00%
GDERF
0.00%
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond

ZUG, Switzerland, March 06, 2025--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2024, delivering strong results for another consecutive year while making significant progress with its blockbuster platforms and future growth drivers.

Business Wire last month

GALDY
0.00%
GDERF
0.00%
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum

ZUG, Switzerland, March 03, 2025--Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando, Florida. The company will present 22 e-posters – including two oral presentations – with updates on a number of its innovative products, including Nemluvio, Sculptra, Restylane and Relfydess. These presentations combined reinforce the strength of Galderma’s growth journey, its s

Business Wire last month

GALDY
0.00%
GDERF
0.00%
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

ZUG, Switzerland, February 18, 2025--Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or cal

Business Wire last month

GALDY
0.00%
GDERF
0.00%
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

ZUG, Switzerland, February 14, 2025--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now approved for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who

Business Wire last month

GALDY
0.00%
GDERF
0.00%
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

ZUG, Switzerland, January 31, 2025--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown lines (glabellar lines)1. Galderma’s analysis was presented at the International Master Course on Aging Science (IM

Business Wire 2 months ago

GALDY
0.00%
GDERF
0.00%
Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

ZUG, Switzerland, January 30, 2025--Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population.

Business Wire 2 months ago

GALDY
0.00%
GDERF
0.00%
IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

ZUG, Switzerland, January 23, 2025--Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 – February 1 in Paris, France. The company will share ten research e-posters with data that differentiate its injectable aesthetic products, including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Mast

Business Wire 2 months ago

GALDY
0.00%
GDERF
0.00%
Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

ZUG, Switzerland, January 14, 2025--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.1 The results will be presented

Business Wire 2 months ago

GALDY
0.00%
GDERF
0.00%
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

ZUG, Switzerland, December 13, 2024--Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcut

Business Wire 3 months ago

GALDY
0.00%
GDERF
0.00%
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

ZUG, Switzerland, December 13, 2024--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged

Business Wire 3 months ago

GALDY
0.00%
GDERF
0.00%
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

ZUG, Switzerland, November 28, 2024--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology.1 The trial met both primary and all key secondary endpoints, showing that nemolizumab-treated patients had significantly higher improvements in itch and skin lesions when compared to those receiving pl

Business Wire 4 months ago

GALDY
0.00%
GDERF
0.00%
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

ZUG, Switzerland, November 04, 2024--This month marks the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation.1-5,10-16 Sculptra works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance, and has been a cornerstone of Galderma’s broad portfolio of proven aesthetic treatments.17,18 During its 25 years on the market, healthcare professionals have treated m

Business Wire 5 months ago

GALDY
0.00%
GDERF
0.00%
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

SINGAPORE, October 25, 2024--Galderma (SWX:GALD), the pure-play dermatology category leader, today announced a new edition of the Galderma Aesthetic Injector Network (GAIN) event in the Asia-Pacific region, which houses some of the company’s fastest growing markets. This is the largest regional event to date and will deliver a premium and engaging experience for more than 650 delegates. Taking place October 26-27 in Incheon, South Korea, the extensive, two-day agenda will take a deep dive into t

Business Wire 5 months ago

GALDY
0.00%
GDERF
0.00%
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

ZUG, Switzerland, October 24, 2024--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2024, reporting record net sales and significant progress across its product categories and key future growth drivers.

Business Wire 5 months ago

GALDY
0.00%
GDERF
0.00%
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

ZUG, Switzerland, October 21, 2024--Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess™) for frown lines and crow’s feet after repeated injections.1 The READY-4 study met its primary and secondary endpoints, with less than one in five participants experiencing treatment-related treatment-emergent adverse events (TEAEs), and all events deemed mild or moderate.1 Efficacy and patient satisfaction were als

Business Wire 5 months ago

GALDY
0.00%
GDERF
0.00%

Performance Overview

Return	GDERF	MSCI WORLD (^990100-USD-STRD)
YTD	+11.44%	-6.66%
1-Year	+40.19%	+2.71%
3-Year	+40.19%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GALDERMA GROUP AG (GDERF)

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

Galderma's Differin is helping destigmatize acne care with first in category Roblox experience

Galderma Group AG (XSWX:GALD) Full Year 2024 Earnings Call Highlights: Record Sales and ...

Galderma Shares Slide on Expected Hit From Investments

Galderma to discuss U.S. tariffs with retailers, sees "moving target"

Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond

AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

Performance Overview